Kailera Therapeutics (KLRA) Q3 2026 earnings summary

Executive summary

• Four-candidate obesity pipeline spans GLP-1-based mechanisms and oral and injectable formulations; no product revenue and continued operating losses as programs advance.

• Cash, cash equivalents and marketable securities totaled $1,037.6 million at September 30, 2026; management expects funding to last into mid-2028.

Financial highlights

• Q3 2026 R&D expense was $84.7 million vs. $27.0 million in Q3 2025; G&A was $21.7 million vs. $13.1 million.

• Q3 operating loss was $106.3 million and net loss was $95.7 million, vs. $40.1 million and $39.6 million, respectively, in Q3 2025.

• Q3 interest income rose to $10.6 million from $2.3 million YoY, primarily reflecting higher cash and marketable securities balances.

• 9M 2026 R&D was $256.6 million, G&A $55.8 million, operating loss $312.4 million and net loss $285.8 million.

• 9M operating cash use was $279.5 million; investing cash use was $437.3 million and financing cash inflow was $663.1 million.

Outlook and guidance

• R&D expense is expected to increase substantially with ribupatide injection Phase 3, planned ribupatide oral Phase 3, and continued safiglipron and KAI-4729 development.

• Ribupatide oral Phase 3 is expected to start in 1H 2027; safiglipron Phase 2 data and ribupatide injection Phase 2b high-dose data are expected mid-2027.

• Ribupatide injection Phase 3 data are expected mid-2028; KAI-4729 Phase 1 data are anticipated in 2027.

• Available cash, cash equivalents and marketable securities are expected to fund operations into mid-2028; estimates depend on assumptions and resources could be used sooner.